Evaluation of PD-L1 expression in tumor tissue

Jovevska, Svetlana and Kondeva, Marija (2021) Evaluation of PD-L1 expression in tumor tissue. Knowledge – International Journal, 45 (4). pp. 789-795.

	Text Насловна.pdf Download (641kB)
	Text EVALUATION OF PD-L1 EXPRESSION IN TUMOR TISSUE.pdf Download (418kB)

Abstract

The interaction between the immune system and cancer cells is complex. Cancer cells can
avoid immune destruction by suppressing the immune system. Tumors can create an immunosuppressive
microenvoirment and therefore cytotoxic T lymphocytes (CTL) can't lysate them. Avoidance of the immune
response is through the inhibitory ligand PD-L1, which is found on the surface of cells of the immune system,
mesenchymal, epithelial, and endothelial cells as well as tumor cells. PD-1 is a surface cell receptor, part of the
immunoglobulin family. Its ligand PD-L1 is expressed by tumor cells and stromal tumor infiltrating lymphocytes
(TIL). This information has been used to increase the therapeutic possibilities for many malignant diseases.
Objectives: 1.Optimization of immunohistochemical method (IHH) with antibody staining, anti PD-L1.
2. Optimization of the evaluation method while using different clones of antibodies.
Material and methods: In this study are included 44 samples from 3 different types of cancer. 24 triple-negative
breast cancers (TNBC), 10 non-small cell lung cancer (NSCLC) and 10 malignant melanoma. Monoclonal mouse
primary antibodies have been used by manufacturers Quartett (QR1) and Ventana (SP 142, SP263). To visualize the
reaction, an ultraView Universal DAB Detection Kit from Ventana was used on an automated platform for
immunohistochemical staining Ventana BenchMark GX. The statistical analysis was done with the statistical
package SPSS for Windows Version 22.0.
Results: With comparing the sensitivity of two different clones on the same tissue samples from triple-negative
breast cancer (TNBC), it can be conclude that the Clone QR1 gives more positive results than the Clone SP142, but
there is no statistically significant difference.
With comparing the sensitivity of two different clones in the same tissue samples from malignant melanoma, it can
be conclude that Clone SP263 gives more positive results than Clone QR1, but there is no statistically significant
difference.
With comparing the sensitivity of two different clones in the same tissue samples from non- small cell lung cancer,
we concluded that Clone QR1 gives more positive results than Clone SP142, but there was no statistically
significant difference.
Conclusion: Use of any of these clones of the manufacturers Quartett and Ventana give satisfactory results and can
be used in the determination and evaluation of PD-L1 status in patients, and thus to determine further therapy and
outcome of patients.
Keywords: breast cancer, malignant melanoma, non-small cell lung cancer, immunohistochemistry, antibodies

Item Type:	Article
Subjects:	Medical and Health Sciences > Clinical medicine
Divisions:	Faculty of Medical Science
Depositing User:	Svetlana Jovevska
Date Deposited:	21 Sep 2021 09:07
Last Modified:	21 Sep 2021 09:07
URI:	https://eprints.ugd.edu.mk/id/eprint/28469

Actions (login required)

View Item